Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $19.8052W HIGH $44.00
Volume
4.35 K
Value Traded
3.39 M
Short % Float
7.61%
Days to Cover
3.3
-2.93%Week
-14.32%1 Month
-15.7%3 Month
-11.05%6 Month
-65.18%5 Year
-93.86%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
103.00 M
EPS (TTM)
-1.20
P/E Ratio
-
Ent. Value
16.35 M
Total Shares
3.94 M
Float Shares
2.06 M
Insiders
47.93%
Institutions
30.81%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
VTVT Catalyst Timeline
Dated clinical, regulatory and corporate events for vTv Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for vTv Therapeutics Inc.
299Total events
5Upcoming
87Tier-1 (high impact)
2015 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Oral PresentationCadisegliatinFiledPresentation
Oral presentation of hypoglycemia burden research at Breakthrough T1D Clinical & Research Congress 2026
type 1 diabetessource ↗
▲Orphan Drug DesignationHPPDDesignation
FDA grants Orphan Drug Designation to HPPD for sickle cell disease
sickle cell diseasesource ↗
▲Enrollment CompleteCadisegliatinFiledTrial
Completed enrollment of Phase 3 CATT1 study of cadisegliatin in T1D (166 patients randomized)
Type 1 Diabetes (T1D)source ↗
▲Enrollment CompleteCadisegliatinFiledTrial
CATT1 trial expected to complete enrollment in Q3 2026
type 1 diabetessource ↗
◆Oral PresentationCadisegliatinFiledPresentation
Alliance Global Partners Healthcare Company Showcase Fireside Chat
type 1 diabetessource ↗
◆Oral PresentationCadisegliatinFiledPresentation
H.C. Wainwright 4th Annual BioConnect Investor Conference Fireside Chat
type 1 diabetessource ↗
▲Partnership / LicenseHPP737Corporate
Amended license agreement with Newsoara for global rights to HPP737
psoriasissource ↗
▲Partnership / LicenseHPP737Corporate
Amended licensing agreement with Newsoara for HPP737, including $20M upfront payment
▲First Patient DosedCadisegliatinFiledTrial
First patient first visit expected for Phase 2 trial of cadisegliatin in type 2 diabetes
type 2 diabetessource ↗
◆Topline ReadoutCadisegliatinFiledClinical Data
Top-line data from first Phase 3 trial of cadisegliatin for T1D expected
type 1 diabetessource ↗
●Trial InitiationCadisegliatinFiledTrial
Phase 2 clinical study protocol submitted to UAE DOH for cadisegliatin in type 2 diabetes
type 2 diabetessource ↗
●IND SubmissionCadisegliatinFiledIND
Phase 2 clinical study protocol submitted to UAE Department of Health for cadisegliatin in type 2 diabetes
type 2 diabetessource ↗
◆Oral PresentationTTP-RAPresentation
Presentation of new preclinical data for TTP-RA at INNODIA Symposium during EASD 61st Annual Meeting
type 1 diabetessource ↗
◆Oral PresentationCadisegliatinFiledPresentation
Update on cadisegliatin Phase 3 study (CATT1) presented at INNODIA Symposium
type 1 diabetessource ↗
◆Oral PresentationPresentation
Morgan Stanley 23rd Annual Global Healthcare Conference Fireside Chat
◆Oral PresentationPresentation
H.C. Wainwright 27th Annual Global Investment Conference 1x1 Meetings
▼Equity OfferingCorporate
$80 million private placement with healthcare institutional investors and T1D Fund
▲Patent GrantedCadisegliatinFiledIP / Competition
USPTO Notice of Allowance for patent covering crystalline forms of cadisegliatin
type 1 diabetessource ↗
▲First Patient DosedCadisegliatinFiledTrial
First participant randomized in CATT1 Phase 3 trial
type 1 diabetessource ↗
▲First Patient DosedCadisegliatinFiledTrial
First study participant randomized in Phase 3 CATT1 trial
type 1 diabetessource ↗
▲Patent GrantedCadisegliatinFiledIP / Competition
USPTO allowed claims for crystalline salt form patent
▲First Patient DosedCadisegliatinFiledTrial
First patient randomized in Phase 3 CATT1 trial
type 1 diabetessource ↗
▲Patent GrantedCadisegliatinFiledIP / Competition
Issuance of new U.S. patent covering crystalline salts and co-crystals forms of cadisegliatin with exclusivity expected out to 2041
◆Oral PresentationPresentation
vTv Therapeutics to participate in H.C. Wainwright HCW@Home Series fireside chat
▲Trial InitiationCadisegliatinFiledTrial
Reinitiation of screening in CATT1 Phase 3 trial for cadisegliatin
type 1 diabetessource ↗
▲Enrollment CompleteCadisegliatinFiledTrial
Screening reinitiated in CATT1 Phase 3 trial
type 1 diabetessource ↗
▲Protocol AmendmentCadisegliatinFiledTrial
Protocol amendment shortens trial duration from 12 to 6 months
type 1 diabetessource ↗
▲Enrollment UpdateCadisegliatinFiledTrial
Screening reinitiated in CATT1 Phase 3 trial
type 1 diabetessource ↗
●Protocol AmendmentCadisegliatinFiledTrial
Protocol amendment submitted to reduce trial duration from 12 to 6 months
type 1 diabetessource ↗
◆Trial InitiationCadisegliatinFiledTrial
CATT1 Phase 3 trial expected to resume
type 1 diabetessource ↗
◆Protocol AmendmentCadisegliatinFiledTrial
Protocol amendment to shorten CATT1 trial from 12 to 6 months
type 1 diabetessource ↗
▲Clinical Hold LiftedCadisegliatinFiledIND
FDA lifts clinical hold on cadisegliatin program
type 1 diabetessource ↗
●NDA SubmissionTTP399FiledRegulatory Filing
NDA submission for TTP399 in Type 1 Diabetes
Type 1 Diabetessource ↗
◆Oral PresentationPresentation
vTv Therapeutics management to participate in fireside chat at 7th Annual Evercore HealthCONx Conference
Past FDA Catalysts and PDUFA Decisions
How VTVT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2021-06-30 | HPP737 | Phase 1 topline data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 4%
Micro Cap(rank 27 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cadisegliatin Small moleculeNCT06334133 | Diabetes Mellitus, Type 1 | Phase 3 | ACTIVE NOT_RECRUITING | 150 | May 1, 2027 | ||||||
| Cadisegliatin Small moleculeNCT07616206 | Type 1 Diabetes (T1D) | Phase 2 | NOT YET_RECRUITING | 40 | Jun 1, 2027 | ||||||
| TTP399 Small moleculeCompletedNCT02405260 | Diabetes Mellitus, Type 2 | Phase 2 | COMPLETED | 190 | Sep 1, 2016 | ||||||
| TTP399 Small moleculeCompletedNCT03335371 | Diabetes Mellitus, Type 1 | Phase 1 | COMPLETED | 115 | Jan 6, 2020 |
Clinical Trial Results
Readouts, endpoints and source filings for every VTVT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| HPP737 | psoriasis | Phase 1 | 2021-06-29 | HPP737 was 10-100 fold more potent than apremilast in inhibiting the generation of cytokines/chemokines, depending upon the analyte.Read More | vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LPDirector | Grant/Award | 6,000 6,000 held | $0.00 | 06/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VTVT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Samsara BioCapital, LLC | 0.9 % (-25 %) | 11.24 M | 298.50 K |
VTVT Institutional Ownership Trends
VTVT Short Interest
Shares sold short, counted twice a month.
7.61%
Short % of Float
of tradable shares sold short
156.8K
Shares Sold Short
-2.2% vs prior count
3.3 Moderate
Days to Cover
trading days of normal volume to buy every short share back
47.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VTVT ranks across every disease it competes in
Competitive Position is a premium feature
See how VTVT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVTVT News
VTVTvTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
vTv Therapeutics announced an oral presentation by Chief Medical Officer Thomas Strack at the Breakthrough T1D Clinical & Research Congress 2026. The presentation focused on hypoglycemia-related burdens in adults with Type 1 Diabetes (T1D) using automated insulin delivery systems. Cadisegliatin, a novel oral therapy, is being evaluated as an adjunctive treatment for T1D. The findings highlight ongoing challenges in managing hypoglycemia despite advancements in insulin technology.
Read more →VTVTvTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
vTv Therapeutics announced that the FDA has granted Orphan Drug Designation to HPPD, an oral therapy for sickle cell disease. This designation highlights the urgent need for new treatments in this area. Preclinical studies indicate that HPPD effectively increases fetal hemoglobin and reduces oxidative stress, supporting its development as a novel therapy.
Read more →VTVTvTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
vTv Therapeutics will host a virtual KOL event on October 20, 2026, focusing on hypoglycemia in type 1 diabetes and the cadisegliatin Phase 3 program. Leading experts will discuss the challenges of living with T1D and the ongoing Phase 3 CATT1 trial of cadisegliatin. The event will include a Q&A session and will be available for replay afterward.
Read more →VTVTvTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
vTv Therapeutics has completed enrollment in its Phase 3 CATT1 study for cadisegliatin, an oral therapy for Type 1 Diabetes. A total of 166 patients were randomized to evaluate the drug's efficacy and safety. The study aims to assess cadisegliatin's potential to reduce hypoglycemia while improving glycemic control. Topline results are expected in mid-2027.
Read more →VTVTvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
vTv Therapeutics has granted 2,500 stock options to a non-executive employee as an inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $31.44 per share and will vest over four years. The company is advancing cadisegliatin, a potential first-in-class therapy for type 1 diabetes, currently in a Phase 3 trial.
Read more →VTVTvTv Therapeutics to Participate in September Investor Conferences
vTv Therapeutics Inc. will participate in two investor conferences in September 2026, showcasing their investigational therapy cadisegliatin for type 1 diabetes. The conferences include the H.C. Wainwright 28th Annual Global Investment Conference and the 5th Annual ROTH Healthcare Opportunities Conference. Cadisegliatin is under investigation as a potential first-in-class treatment and has received Breakthrough Therapy designation from the FDA.
Read more →VTVTvTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
vTv Therapeutics reported its financial results for Q2 2026, highlighting progress in its Phase 3 CATT1 trial for cadisegliatin, an oral treatment for type 1 diabetes. The company expects to complete enrollment by Q3 2026 and has sufficient funds to continue operations until the topline data readout. A Key Opinion Leader event is planned for Q4 2026 to discuss cadisegliatin's potential benefits.
Read more →VTVTvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - June 2, 2026
vTv Therapeutics announced the granting of 2,500 stock options to a non-executive employee as an inducement to employment, in line with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $34.30 and will vest over four years. The company is focused on developing cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes, currently in a Phase 3 trial.
Read more →VTVTvTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
vTv Therapeutics reported its financial results for Q1 2026, highlighting progress in its Phase 3 CATT1 trial for cadisegliatin, an oral therapy for type 1 diabetes. The company expects to complete enrollment by Q3 2026 and has a solid cash position to support operations. Additionally, a recent license amendment has strengthened its financial standing.
Read more →VTVTvTv Therapeutics to Participate in Upcoming May Investor Conferences
vTv Therapeutics Inc. announced its participation in two upcoming investor conferences in May 2026, focusing on its lead candidate, cadisegliatin, for type 1 diabetes. The company will engage in a fireside chat format at both events, providing updates on its clinical pipeline. Cadisegliatin is currently in a Phase 3 trial and has received Breakthrough Therapy designation from the FDA.
Read more →VTVTvTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 7, 2026
vTv Therapeutics announced the grant of 4,000 stock options to a non-executive employee as part of an inducement to employment under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $39.54 and will vest over four years. The company is advancing its lead candidate, cadisegliatin, a potential first-in-class treatment for type 1 diabetes, currently in a Phase 3 trial.
Read more →VTVT▲ +14.6%on this news
vTv Therapeutics to Participate in the 38th Annual ROTH Conference
vTv Therapeutics Inc. announced its participation in the 38th Annual ROTH Conference, scheduled for March 22-24, 2026, in Dana Point, CA. The company will engage in a fireside chat and hold one-on-one investor meetings. Cadisegliatin, their lead candidate, is under investigation as a potential first-in-class oral adjunctive therapy for type 1 diabetes and is currently in a Phase 3 trial.
Read more →VTVTvTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
vTv Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting a net loss of $27 million for the year. The company received an additional $20 million from Newsoara under a licensing agreement and expects to complete enrollment for its CATT1 Phase 3 trial by the third quarter of 2026. vTv has significantly strengthened its financial position, with increased cash reserves allowing for a funding runway beyond the anticipated topline readout. The firm continues to focus on the development of cadisegliatin for type 1 diabetes and has expanded its advisory board to support this effort.
Read more →VTVT▼ -7.2%on this news
vTv Therapeutics to Participate in Upcoming Investor Conferences
vTv Therapeutics Inc. announced its participation in two upcoming investor conferences, highlighting its focus on cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes. The company is currently conducting a Phase 3 trial for this drug, which has received Breakthrough Therapy designation from the FDA. However, the safety and efficacy of cadisegliatin remain unproven.
Read more →VTVT▲ +8.2%on this news
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
vTv Therapeutics has amended its license agreement with Newsoara Biopharma, granting Newsoara exclusive worldwide rights to develop and commercialize the PDE4 inhibitor HPP737. This strategic move includes a $20 million upfront payment and potential future milestone payments totaling approximately $115 million. The partnership aims to enhance the clinical development of HPP737, which has shown promise in treating inflammation-mediated diseases.
Read more →About vTv Therapeutics Inc.
Headquarters3980 PREMIER DR, HIGH POINT, NC, 27265
BIOPHARMAWATCH ELITE PLUS
Trade the next VTVT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime